Lamotrigine

• Epilepsy
• Bipolar Disorder
• Seizure Prevention
• Mood Stabilization

Lamotrigine is an anticonvulsant medication used for the treatment of epilepsy and bipolar disorder. This medication works through voltage-sensitive sodium channel blockade and offers unique benefits in bipolar disorder for preventing depressive episodes while having a favorable side effect profile.

Mechanism of Action

Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the presynaptic release of excitatory neurotransmitters, particularly glutamate. By blocking sodium channels in their inactivated state, lamotrigine preferentially reduces high-frequency repetitive firing of action potentials that occurs during seizure activity. The reduction in glutamate release may also contribute to its mood-stabilizing effects in bipolar disorder. Unlike some other mood stabilizers, lamotrigine's mechanism does not appear to involve significant effects on GABA transmission or monoamine neurotransmitter systems.

Available Formulations

Lamotrigine is available as immediate-release tablets (25 mg, 100 mg, 150 mg, 200 mg), chewable/dispersible tablets (2 mg, 5 mg, 25 mg), extended-release tablets (25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg), and orally disintegrating tablets (25 mg, 50 mg, 100 mg, 200 mg). Different formulations are not equivalent on a mg-per-mg basis. Generic formulations are available.

Medical Uses

Lamotrigine is FDA-approved for adjunctive therapy for seizures in patients aged 2 years and older with generalized seizures of Lennox-Gastaut syndrome, adjunctive therapy for primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset seizures, conversion to monotherapy in patients with partial-onset seizures receiving a single enzyme-inducing antiepileptic drug, and maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes. It is particularly effective in preventing depressive episodes in bipolar disorder.

Dosing Guidelines

Lamotrigine requires very slow dose titration to minimize the risk of serious rash. Initial doses and titration schedules vary significantly depending on whether the patient is taking enzyme-inducing anticonvulsants (e.g., carbamazepine, phenytoin) or valproate, which inhibits lamotrigine metabolism. For patients not taking these interacting drugs, typical starting dose is 25 mg daily for 2 weeks, then 50 mg daily for 2 weeks, with subsequent increases every 1-2 weeks. Maximum doses range from 200-500 mg daily depending on indication and concomitant medications.

Important Safety Information

Lamotrigine carries a boxed warning for serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal. The risk of serious rash is increased by rapid dose escalation, concurrent use of valproate, and exceeding initial recommended doses. Treatment should be discontinued at the first sign of rash unless clearly not drug-related. Other serious risks include hemophagocytic lymphohistiocytosis (HLH), multi-organ hypersensitivity reactions (DRESS), aseptic meningitis, and cardiac conduction abnormalities.

Drug Interactions

Valproate significantly increases lamotrigine levels (requires 50% dose reduction). Enzyme-inducing drugs (carbamazepine, phenytoin, phenobarbital, rifampin) significantly decrease lamotrigine levels (may require higher doses). Estrogen-containing oral contraceptives decrease lamotrigine levels; dose adjustment may be needed during the hormone-free week. Lamotrigine may decrease the efficacy of levonorgestrel-containing contraceptives.

Where Lamotrigine Fits in Bipolar Disorder and Epilepsy

In bipolar disorder, lamotrigine occupies a specific and often misunderstood position: it protects against the depressive pole far better than the manic one. That makes it a strong maintenance choice for the many patients whose illness is dominated by depressive episodes, and a poor choice as a sole agent for someone with frequent mania. It is also not an acute treatment — the titration is far too slow to help a patient who is unwell today, so an acute episode is treated with something else while lamotrigine is built up underneath. Lithium remains the comparator with the strongest evidence against mania and against suicide, and an antipsychotic such as quetiapine covers both poles; combinations are common. Its tolerability is what recommends it: it is weight-neutral, does not require routine blood level monitoring, and lacks the metabolic burden of the antipsychotics.

In seizures, lamotrigine is a broad-spectrum agent effective in both focal and generalized epilepsy, which distinguishes it from the sodium channel blockers that can worsen generalized syndromes. It is frequently chosen in women of childbearing age because its pregnancy profile compares favorably with several alternatives, and in older adults because it is comparatively free of sedation and cognitive slowing. Levetiracetam is the other common broad-spectrum first choice and can be started far faster, which matters when seizures are frequent; its drawback is irritability and mood change in a minority of patients. Topiramate has a role but brings cognitive and word-finding complaints.

The Titration Is the Treatment

Almost everything that goes wrong with lamotrigine goes wrong during the start. The risk of a serious rash is tied to how quickly the dose is raised, and the slow schedule described above is not a formality to be compressed when a patient is impatient or a clinic visit is delayed. The starter packs exist precisely because the schedule is easy to get wrong from a standard prescription.

Three failures recur. The first is dose escalation faster than the schedule allows, including a well-meant increase made because the patient is not yet better. The second is failing to adjust for interacting medications: valproate roughly doubles exposure and requires a halved schedule, while enzyme-inducing anticonvulsants do the opposite, and starting either drug in a patient already on lamotrigine changes the target. The third is a treatment gap. If several days of doses are missed — a lost prescription, a hospital admission, a lapse in insurance — the drug largely clears, and treatment is restarted from the beginning of the titration rather than resumed at the previous dose. Patients should be told this before it happens, because the instinct is to take the old dose.

Any rash during the titration period is treated as the drug's until proven otherwise; the medication is stopped and the patient is assessed the same day rather than told to watch it, and fever, facial or mucosal involvement, blistering, or feeling systemically unwell warrants emergency evaluation. The MedlinePlus lamotrigine monograph states this plainly for patients, and the NINDS overview of epilepsy and seizures explains how anticonvulsants are selected. Our neurologic and psychiatric colleagues manage the two indications, which are prescribed and monitored differently even though the tablet is the same.

Special Populations

Lamotrigine has data suggesting relatively safer use during pregnancy compared to some other anticonvulsants, though there is an increased risk of oral clefts with first trimester exposure. Plasma levels may change during pregnancy, requiring monitoring. It is excreted in breast milk; effects on nursing infants are unclear. Safety and efficacy have been established in pediatric patients aged 2 years and older for epilepsy. Elderly patients may require lower doses. Dose reduction is required in moderate and severe hepatic impairment. No dose adjustment is typically needed for renal impairment, though caution is advised in severe impairment.